This may be of interest to members.
In May 2022 the National Blood Authority (NBA) announced that five of Australia’s domestic plasma products will be changing. More information on these transitions can be found here: Transition of Australia’s domestic plasma products.
This particular notification refers to Australia’s three factor prothrombin complex concentrate (PCC), PROTHROMBINEX-VF. This product will be replaced with a four factor PCC containing clotting factors II, VII, IX and X in 2024.
It is anticipated PROTHROMBINEX-VF will be available until around June 2024. To ensure there is continued access to human PCC between that time and when the domestic replacement BERIPLEX AU will become available in late 2024/early 2025, a short-term supply of BERIPLEX P/N (an imported product manufactured with plasma collected overseas) will take place.
More information about the initial transition from PROTHROMBINEX-VF to BERIPLEX P/N, including product information, timing and implementation will be released in BloodNet and the Australian Bleeding Disorders Registry in early 2024.
Please direct any queries to the National Blood Authority at Supply.Management.Plasma@blood.gov.au or 13 000 BLOOD (13 000 25663).